Latest news with #Immunotherapy
Yahoo
2 days ago
- Business
- Yahoo
[Latest] Global Neoantigen Cancer Vaccine Market Size/Share Worth USD 1.98 Billion by 2034 at a 15.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Neoantigen Cancer Vaccine Market size & share revenue was valued at approximately USD 0.49 Billion in 2024 and is expected to reach USD 0.55 Billion in 2025 and is expected to reach around USD 1.98 Billion by 2034, at a CAGR of 15.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are OSE Immunotherapeutics SA, Gritstone bio Inc., BioNTech SE, Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Moderna Inc., Avidea Technologies Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co. Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co. Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis Inc, and others. Austin, TX, USA, June 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of global Neoantigen Cancer Vaccine Market size & share was valued at approximately USD 0.49 Billion in 2024 and is expected to reach USD 0.55 Billion in 2025 and is expected to reach a value of around USD 1.98 Billion by 2034, at a compound annual growth rate (CAGR) of about 15.2% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Neoantigen Cancer Vaccine Market Overview As per the industry experts at CMI, the Neoantigen Cancer Vaccine Market is quickly growing as a result of the significance placed on personalized cancer therapies. The leading companies include OSE Immunotherapeutic SA, Gritstone Bio Inc., BioNTech SE, Hoffmann-La Roche Ltd and Pfizer Inc., all of whom are developing individualized cancer vaccines targeting patient-specific tumor neoantigens to enhance the immune response. Various malignancies are receiving these vaccines to enhance their outcomes. Governments are supporting clinical trials and exploring fast-track CRA regulatory approvals to help accelerate the process and innovations. The pharma, biotechnology, and research community continue driving collaborations to advance cancer vaccines. Investment funding is increasing in the neoantigen cancer vaccine products globally—North America, Europe and Asia- pacific are the top three regions. This experience will add a new wave of molecularly-targeted and precisely effective cancer immunotherapies to the suite of effective pharmaceutical therapies worldwide. Neoantigen Cancer Vaccine Market Growth Factors and Dynamics Increasing incidence of cancer: The increasing incidence of cancer worldwide is a driving force behind the growth of the neoantigen cancer vaccine market. The increasing incidence of cancer creates a large demand for innovative, personalized therapies. Neoantigen vaccines designed to target mutations unique to an individual's tumor provide a breaking point in addressing multiple cancers effectively. The recent, notable positive Phase 2 results by BioNTech for its mRNA immunotherapy candidate BNT111 in patients with advanced melanoma in 2024 illustrate a greater focus on personalized cancer therapies. Furthermore, the increasing incidence of cancer diagnoses shown by the U.S. National Cancer Institute provides a pertinent need for advanced therapies like neoantigen vaccines. Advances in delivery systems: Advances in delivery systems for vaccines, such as lipid nanoparticles and viral vectors, have provided stability, targeting, and greater efficacy regarding neoantigen vaccines, in addition to improving clinical response and efficacy in personalized cancer therapies. Again, the international Phase 3 'Artemia' trial, which was launched by OSE Immunotherapeutics in 2024, is noteworthy. This Phase 3 trial is for Tedopi, an 'off-the-shelf' neo-epitope-based cancer vaccine for HLA-A2-positive patients with metastatic non-small cell lung cancer (NSCLC) and lethargy who developed secondary resistance to immune checkpoint inhibitors. This pivotal trial aims to gain regulatory approval for Tedopi. This is a meaningful advancement in the neoantigen vaccine delivery system and cancer treatment. Increased cancer incidence: The incidence of cancer worldwide is one of the major factors propelling growth of the neoantigen cancer vaccine market. As pointed out by the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 20 million new cases and 10 million deaths every year. The increasing rates of cancer demand new, more effective, and targeted treatments other than the traditional ones of chemotherapy and radiation. Neoantigen cancer vaccines are unique and extremely specific personalized therapies that stimulate the immune system to identify and attack cancer cells 'with laser precision', without employing belated-acting toxic treatments like chemotherapy and radiation on healthy tissue. The increasing rates of difficult to treat cancers such as melanoma, non-small cell lung cancer, and particularly glioblastoma hold potential for these types of precision-based immunotherapy. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Advancements in Immunotherapy: Recent breakthroughs in immunotherapy have significantly contributed to the emergence and expansion of the neoantigen cancer vaccine market. Immunotherapy has revolutionized oncology by offering treatments that harness the body's immune system to target and eliminate cancer cells. Among these, neoantigen vaccines represent a cutting-edge class of therapies that are personalized based on tumor-specific mutations, making them uniquely suited for individualized treatment strategies. Innovations such as checkpoint inhibitors, CAR-T cells, and adoptive T-cell therapies have validated the immune system's potential in combating cancer, laying the groundwork for further development of neoantigen approaches. Additionally, the integration of advanced computational biology and next-generation sequencing technologies enables rapid identification and synthesis of neoantigens, accelerating vaccine production timelines and improving therapeutic outcomes. These technological advancements are critical in transforming experimental treatments into viable commercial products. Report Scope Feature of the Report Details Market Size in 2025 USD 0.55 Billion Projected Market Size in 2034 USD 1.98 Billion Market Size in 2024 USD 0.49 Billion CAGR Growth Rate 15.2% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product, Neoantigen Type, Route of Administration and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Neoantigen Cancer Vaccine report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Neoantigen Cancer Vaccine report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Neoantigen Cancer Vaccine Market SWOT Analysis Strengths: Neoantigen cancer vaccines offer a significant degree of personalization in treatment as they target the specific mutations that can be found in each patient's tumors, which promotes precision in treatment. They have demonstrated great potential in treating cancers not otherwise treatable with standard therapies. In addition, the advances of both genomic sequencing and mRNA and its abbreviated immunogenicity promise, neoantigen cancer vaccines have the potential to show equally enhanced immunogenicity. Growing investment from major biotech firms and government agencies supports rapid R&D. Regulatory agencies like the FDA and EMA are offering fast-track approvals. Early clinical trials, especially in melanoma and NSCLC, have demonstrated promising results. Weaknesses: High development costs and complex production processes limit scalability and accessibility. The need for advanced genomic sequencing and bioinformatics infrastructure creates technical bottlenecks. Turnaround time for creating personalized vaccines can be lengthy. Reimbursement challenges exist due to the novel nature of the therapy. Limited long-term efficacy data in many cancer types also restricts broader adoption. Workforce and supply chain challenges can delay progress, as seen in recent clinical trial halts. Opportunities: Some developing markets such as India, Brazil, and South Africa present new opportunities for clinical expansion. Off-the-shelf vaccine approaches may provide the opportunity for scalability and reduced cost. Improved AI and bioinformatics technology may increase neoantigen prediction accuracy and ease of vaccine design. Biotech and healthcare companies are entering into strategic collaborative agreements, which are improving access. Governments and organizations are interested in funding initiatives in personalized cancer care. Increasing global incidence of cancer is increasing demand for new therapies. Threats: As immunotherapies increase competition from other immunotherapies such as checkpoint inhibitors and CAR-T cells, this will cannibalize market share. Regulatory challenges and lack of standards in approvals may increase timeframes. Investor confidence may be challenged due to late-stage clinical trial failures potentially demonstrated by Gritstone Bio, which affect confidence in further investment into the new treatment that is a neoantigen cancer vaccine. The type of information shared digitally is related to genomic data and presents cybersecurity challenges. There may also be pricing barriers for access within the healthcare systems due to potential sensitivity towards the cost of the intervention. Similarly, I believe that we can expect frequent patent disputes and IP threats associated with the emergence of personalised cancer therapy. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Key questions answered in this report: What is the size of the Neoantigen Cancer Vaccine market and what is its expected growth rate? What are the primary driving factors that push the Neoantigen Cancer Vaccine market forward? What are the Neoantigen Cancer Vaccine Industry's top companies? What are the different categories that the Neoantigen Cancer Vaccine Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Neoantigen Cancer Vaccine market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ Neoantigen Cancer Vaccine Market Regional Perspective The Neoantigen Cancer Vaccine Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: In the US, substantial advances have been made in neoantigen cancer vaccine research. For example, a Phase I trial at the Dana-Farber Cancer Institute showed results from a personalized neoantigen vaccine for advanced kidney cancer, with all nine patients being cancer-free after a median follow-up of 35 months with no serious adverse events. Mount Sinai researchers showed that a multi-peptide neoantigen cancer vaccine induced strong immune responses across multiple cancers in a Phase I trial. Moreover, Memorial Sloan Kettering Cancer Center shared an early-phase clinical trial, which demonstrated an investigational mRNA vaccine can induce sustained immune activity in pancreatic cancer patients. Europe: European organizations are also making incremental research advances in neoantigen vaccines. At the 2024 American Association for Cancer Research (AACR) Annual Meeting, researchers from Institut Curie in Paris presented findings of a therapeutic cancer vaccine developed for each individual tumor. The therapeutic cancer vaccine showed strong immune responses when applied in a head and neck squamous cell carcinoma patient cohort. Transgene and NEC Corporation presented follow-up data from their Phase I trial of their individualized cancer vaccine, TG4050, in a cohort of head and neck cancer patients and will be commencing a randomized Phase II extension of the trial. The UK-based National Health Service (NHS) started trials. Asia-Pacific: In the Asia-Pacific region, collaborative efforts have been made to advance neoantigen vaccine development. In March 2024, Boston Gene, NEC, and Transgene joined forces to advance their Phase I/II clinical trial for the neoantigen cancer vaccine TG4050, aiming to harness personalized medicine to combat cancer. Additionally, Everest Medicines announced financial results highlighting their efforts in developing a vaccine designed to encode dozens of tumor neoantigens using a lipid nanoparticle delivery system for efficient delivery of neoantigen-encoded mRNA. LAMEA: The Relative scarcity of reporting on advances being made in developing neoantigen cancer vaccines in LAMEA has also resulted in much less excitement about the field. Still, LAMEA is witnessing increasing interest in cancer immunotherapy. Many collaborations and clinical trials are expanding to include populations outside the continent and share genetic backgrounds to better understand the efficacy and safety of these personalized cancer therapies. These types of moves in LAMEA will be critical for the global usability of neoantigen vaccines, and there is a great deal of support for these undertakings via global partnerships, as well as, development in the health infrastructure related to very early stage research. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Neoantigen Cancer Vaccine Market: OSE Immunotherapeutics SA Gritstone bio Inc. BioNTech SE Hoffmann-La Roche Ltd. Pfizer Inc. Merck & Co. Inc. Moderna Inc. Avidea Technologies Inc. Eli Lilly and Company Vaccibody AS Agenus Inc. Novogene Co. Ltd. ZIOPHARM Oncology Inc. ISA Pharmaceuticals B.V. BrightPath Biotherapeutics Co. Ltd. Vaximm AG Medigene AG Genocea Biosciences Inc. Advaxis Inc. Others Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Japan Cell Cancer Vaccine Market: Japan Cell Cancer Vaccine Market Size, Trends and Insights By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Oncolytic Viruses), By Indication (Prostate Cancer, Cervical Cancer), By Technology (Peptide-based Vaccines, Vector-based Vaccines, DNA/RNA-based Vaccines), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 mRNA Cancer Vaccine Market: mRNA Cancer Vaccine Market Size, Trends and Insights By Cancer Type (Melanoma, Lung Cancer (NSCLC), Prostate Cancer, Pancreatic Cancer, Colorectal Cancer), By Application/Use Case (Therapeutic Cancer Vaccines, Preventive/Prophylactic Cancer Vaccines), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Carriers, Electroporation), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Peptide Cancer Vaccine Market: Peptide Cancer Vaccine Market Size, Trends and Insights By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Burial Insurance Market: Burial Insurance Market Size, Trends and Insights By Coverage (Level Death Benefit, Guaranteed Acceptance, Modified or Graded Death Benefit), By End Use (Over 50, Over 60, Over 70, Over 80), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Organoids and Spheroids Market: Organoids and Spheroids Market Size, Trends and Insights By Organoids Type (Neural Organoids, Hepatic Organoids, Intestinal Organoids, Other Organoids), By Spheroids Type (Multicellular Tumor Spheroids (MCTS), Neurospheres, Mammospheres, Hepatospheres, Embryoid Bodies), By Organoids Source (Primary Tissues, Stem Cells), By Spheroids Source (Cell Line, Primary Cell, iPSCs Derived Cells), By End User (BioSource and Pharmaceutical Industries, Academic & Research Institutes, Hospitals and Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Medical Education Market: Medical Education Market Size, Trends and Insights By Delivery Mode (Classroom-based Training, E-learning Solutions, Online Learning, Simulation-based Learning, AR/VR-based Training, AI-powered Learning), By End User Type (Medical Schools and Universities, Hospitals and Healthcare Organizations, Independent Training Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Electrophysiology Devices Market: Electrophysiology Devices Market Size, Trends and Insights By Type (Ablation Catheters, Diagnostic Catheters, Mapping System, Accessories, Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, Others), By End User (Hospitals & ASCs, Specialty Clinics & Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Vitreous Tamponades Market: Vitreous Tamponades Market Size, Trends and Insights By Product Type (Gaseous Tamponades, Liquid Tamponades, Silicone Oil, Perchloroethane, Others), By Application (Retinal Detachment, Macular Hole, Endophthalmis, Intraocular Tumours, Vitreous Haemorrhage, Others), By End User (Hospitals, Ophthalmology Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 The Neoantigen Cancer Vaccine Market is segmented as follows: By Product Personalised neo-antigen vaccine Off-the-shelf neoantigen vaccine By Neoantigen Type Synthetic Long Peptide Nucleic acid Dendritic cell Tumour cell By Route of Administration Intravenous Intramuscular Transdermal Click Here to Get a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Neoantigen Cancer Vaccine Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Neoantigen Cancer Vaccine Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Neoantigen Cancer Vaccine Market? What Was the Capacity, Production Value, Cost and PROFIT of the Neoantigen Cancer Vaccine Market? What Is the Current Market Status of the Neoantigen Cancer Vaccine Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Neoantigen Cancer Vaccine Market by Considering Applications and Types? What Are Projections of the Global Neoantigen Cancer Vaccine Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Neoantigen Cancer Vaccine Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Neoantigen Cancer Vaccine Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Neoantigen Cancer Vaccine Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Neoantigen Cancer Vaccine Industry? Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Reasons to Purchase Neoantigen Cancer Vaccine Market Report Neoantigen Cancer Vaccine Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Neoantigen Cancer Vaccine Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Neoantigen Cancer Vaccine Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Neoantigen Cancer Vaccine Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Neoantigen Cancer Vaccine market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Neoantigen Cancer Vaccine market analysis. The competitive environment of current and potential participants in the Neoantigen Cancer Vaccine market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Neoantigen Cancer Vaccine market should find this report useful. The research will be useful to all market participants in the Neoantigen Cancer Vaccine industry. Managers in the Neoantigen Cancer Vaccine sector are interested in publishing up-to-date and projected data about the worldwide Neoantigen Cancer Vaccine market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Neoantigen Cancer Vaccine products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
[Latest] Global Neoantigen Cancer Vaccine Market Size/Share Worth USD 1.98 Billion by 2034 at a 15.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Neoantigen Cancer Vaccine Market size & share revenue was valued at approximately USD 0.49 Billion in 2024 and is expected to reach USD 0.55 Billion in 2025 and is expected to reach around USD 1.98 Billion by 2034, at a CAGR of 15.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are OSE Immunotherapeutics SA, Gritstone bio Inc., BioNTech SE, Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Moderna Inc., Avidea Technologies Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co. Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co. Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis Inc, and others. Austin, TX, USA, June 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of global Neoantigen Cancer Vaccine Market size & share was valued at approximately USD 0.49 Billion in 2024 and is expected to reach USD 0.55 Billion in 2025 and is expected to reach a value of around USD 1.98 Billion by 2034, at a compound annual growth rate (CAGR) of about 15.2% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Neoantigen Cancer Vaccine Market Overview As per the industry experts at CMI, the Neoantigen Cancer Vaccine Market is quickly growing as a result of the significance placed on personalized cancer therapies. The leading companies include OSE Immunotherapeutic SA, Gritstone Bio Inc., BioNTech SE, Hoffmann-La Roche Ltd and Pfizer Inc., all of whom are developing individualized cancer vaccines targeting patient-specific tumor neoantigens to enhance the immune response. Various malignancies are receiving these vaccines to enhance their outcomes. Governments are supporting clinical trials and exploring fast-track CRA regulatory approvals to help accelerate the process and innovations. The pharma, biotechnology, and research community continue driving collaborations to advance cancer vaccines. Investment funding is increasing in the neoantigen cancer vaccine products globally—North America, Europe and Asia- pacific are the top three regions. This experience will add a new wave of molecularly-targeted and precisely effective cancer immunotherapies to the suite of effective pharmaceutical therapies worldwide. Neoantigen Cancer Vaccine Market Growth Factors and Dynamics Increasing incidence of cancer: The increasing incidence of cancer worldwide is a driving force behind the growth of the neoantigen cancer vaccine market. The increasing incidence of cancer creates a large demand for innovative, personalized therapies. Neoantigen vaccines designed to target mutations unique to an individual's tumor provide a breaking point in addressing multiple cancers effectively. The recent, notable positive Phase 2 results by BioNTech for its mRNA immunotherapy candidate BNT111 in patients with advanced melanoma in 2024 illustrate a greater focus on personalized cancer therapies. Furthermore, the increasing incidence of cancer diagnoses shown by the U.S. National Cancer Institute provides a pertinent need for advanced therapies like neoantigen vaccines. Advances in delivery systems: Advances in delivery systems for vaccines, such as lipid nanoparticles and viral vectors, have provided stability, targeting, and greater efficacy regarding neoantigen vaccines, in addition to improving clinical response and efficacy in personalized cancer therapies. Again, the international Phase 3 'Artemia' trial, which was launched by OSE Immunotherapeutics in 2024, is noteworthy. This Phase 3 trial is for Tedopi, an 'off-the-shelf' neo-epitope-based cancer vaccine for HLA-A2-positive patients with metastatic non-small cell lung cancer (NSCLC) and lethargy who developed secondary resistance to immune checkpoint inhibitors. This pivotal trial aims to gain regulatory approval for Tedopi. This is a meaningful advancement in the neoantigen vaccine delivery system and cancer treatment. Increased cancer incidence: The incidence of cancer worldwide is one of the major factors propelling growth of the neoantigen cancer vaccine market. As pointed out by the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 20 million new cases and 10 million deaths every year. The increasing rates of cancer demand new, more effective, and targeted treatments other than the traditional ones of chemotherapy and radiation. Neoantigen cancer vaccines are unique and extremely specific personalized therapies that stimulate the immune system to identify and attack cancer cells 'with laser precision', without employing belated-acting toxic treatments like chemotherapy and radiation on healthy tissue. The increasing rates of difficult to treat cancers such as melanoma, non-small cell lung cancer, and particularly glioblastoma hold potential for these types of precision-based immunotherapy. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Advancements in Immunotherapy: Recent breakthroughs in immunotherapy have significantly contributed to the emergence and expansion of the neoantigen cancer vaccine market. Immunotherapy has revolutionized oncology by offering treatments that harness the body's immune system to target and eliminate cancer cells. Among these, neoantigen vaccines represent a cutting-edge class of therapies that are personalized based on tumor-specific mutations, making them uniquely suited for individualized treatment strategies. Innovations such as checkpoint inhibitors, CAR-T cells, and adoptive T-cell therapies have validated the immune system's potential in combating cancer, laying the groundwork for further development of neoantigen approaches. Additionally, the integration of advanced computational biology and next-generation sequencing technologies enables rapid identification and synthesis of neoantigens, accelerating vaccine production timelines and improving therapeutic outcomes. These technological advancements are critical in transforming experimental treatments into viable commercial products. Report Scope Feature of the Report Details Market Size in 2025 USD 0.55 Billion Projected Market Size in 2034 USD 1.98 Billion Market Size in 2024 USD 0.49 Billion CAGR Growth Rate 15.2% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product, Neoantigen Type, Route of Administration and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Neoantigen Cancer Vaccine report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Neoantigen Cancer Vaccine report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Neoantigen Cancer Vaccine Market SWOT Analysis Strengths: Neoantigen cancer vaccines offer a significant degree of personalization in treatment as they target the specific mutations that can be found in each patient's tumors, which promotes precision in treatment. They have demonstrated great potential in treating cancers not otherwise treatable with standard therapies. In addition, the advances of both genomic sequencing and mRNA and its abbreviated immunogenicity promise, neoantigen cancer vaccines have the potential to show equally enhanced immunogenicity. Growing investment from major biotech firms and government agencies supports rapid R&D. Regulatory agencies like the FDA and EMA are offering fast-track approvals. Early clinical trials, especially in melanoma and NSCLC, have demonstrated promising results. Weaknesses: High development costs and complex production processes limit scalability and accessibility. The need for advanced genomic sequencing and bioinformatics infrastructure creates technical bottlenecks. Turnaround time for creating personalized vaccines can be lengthy. Reimbursement challenges exist due to the novel nature of the therapy. Limited long-term efficacy data in many cancer types also restricts broader adoption. Workforce and supply chain challenges can delay progress, as seen in recent clinical trial halts. Opportunities: Some developing markets such as India, Brazil, and South Africa present new opportunities for clinical expansion. Off-the-shelf vaccine approaches may provide the opportunity for scalability and reduced cost. Improved AI and bioinformatics technology may increase neoantigen prediction accuracy and ease of vaccine design. Biotech and healthcare companies are entering into strategic collaborative agreements, which are improving access. Governments and organizations are interested in funding initiatives in personalized cancer care. Increasing global incidence of cancer is increasing demand for new therapies. Threats: As immunotherapies increase competition from other immunotherapies such as checkpoint inhibitors and CAR-T cells, this will cannibalize market share. Regulatory challenges and lack of standards in approvals may increase timeframes. Investor confidence may be challenged due to late-stage clinical trial failures potentially demonstrated by Gritstone Bio, which affect confidence in further investment into the new treatment that is a neoantigen cancer vaccine. The type of information shared digitally is related to genomic data and presents cybersecurity challenges. There may also be pricing barriers for access within the healthcare systems due to potential sensitivity towards the cost of the intervention. Similarly, I believe that we can expect frequent patent disputes and IP threats associated with the emergence of personalised cancer therapy. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ Key questions answered in this report: What is the size of the Neoantigen Cancer Vaccine market and what is its expected growth rate? What are the primary driving factors that push the Neoantigen Cancer Vaccine market forward? What are the Neoantigen Cancer Vaccine Industry's top companies? What are the different categories that the Neoantigen Cancer Vaccine Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Neoantigen Cancer Vaccine market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ Neoantigen Cancer Vaccine Market Regional Perspective The Neoantigen Cancer Vaccine Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: In the US, substantial advances have been made in neoantigen cancer vaccine research. For example, a Phase I trial at the Dana-Farber Cancer Institute showed results from a personalized neoantigen vaccine for advanced kidney cancer, with all nine patients being cancer-free after a median follow-up of 35 months with no serious adverse events. Mount Sinai researchers showed that a multi-peptide neoantigen cancer vaccine induced strong immune responses across multiple cancers in a Phase I trial. Moreover, Memorial Sloan Kettering Cancer Center shared an early-phase clinical trial, which demonstrated an investigational mRNA vaccine can induce sustained immune activity in pancreatic cancer patients. Europe: European organizations are also making incremental research advances in neoantigen vaccines. At the 2024 American Association for Cancer Research (AACR) Annual Meeting, researchers from Institut Curie in Paris presented findings of a therapeutic cancer vaccine developed for each individual tumor. The therapeutic cancer vaccine showed strong immune responses when applied in a head and neck squamous cell carcinoma patient cohort. Transgene and NEC Corporation presented follow-up data from their Phase I trial of their individualized cancer vaccine, TG4050, in a cohort of head and neck cancer patients and will be commencing a randomized Phase II extension of the trial. The UK-based National Health Service (NHS) started trials. Asia-Pacific: In the Asia-Pacific region, collaborative efforts have been made to advance neoantigen vaccine development. In March 2024, Boston Gene, NEC, and Transgene joined forces to advance their Phase I/II clinical trial for the neoantigen cancer vaccine TG4050, aiming to harness personalized medicine to combat cancer. Additionally, Everest Medicines announced financial results highlighting their efforts in developing a vaccine designed to encode dozens of tumor neoantigens using a lipid nanoparticle delivery system for efficient delivery of neoantigen-encoded mRNA. LAMEA: The Relative scarcity of reporting on advances being made in developing neoantigen cancer vaccines in LAMEA has also resulted in much less excitement about the field. Still, LAMEA is witnessing increasing interest in cancer immunotherapy. Many collaborations and clinical trials are expanding to include populations outside the continent and share genetic backgrounds to better understand the efficacy and safety of these personalized cancer therapies. These types of moves in LAMEA will be critical for the global usability of neoantigen vaccines, and there is a great deal of support for these undertakings via global partnerships, as well as, development in the health infrastructure related to very early stage research. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Neoantigen Cancer Vaccine Market: OSE Immunotherapeutics SA Gritstone bio Inc. BioNTech SE Hoffmann-La Roche Ltd. Pfizer Inc. Merck & Co. Inc. Moderna Inc. Avidea Technologies Inc. Eli Lilly and Company Vaccibody AS Agenus Inc. Novogene Co. Ltd. ZIOPHARM Oncology Inc. ISA Pharmaceuticals B.V. BrightPath Biotherapeutics Co. Ltd. Vaximm AG Medigene AG Genocea Biosciences Inc. Advaxis Inc. Others Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Japan Cell Cancer Vaccine Market: Japan Cell Cancer Vaccine Market Size, Trends and Insights By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Oncolytic Viruses), By Indication (Prostate Cancer, Cervical Cancer), By Technology (Peptide-based Vaccines, Vector-based Vaccines, DNA/RNA-based Vaccines), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 mRNA Cancer Vaccine Market: mRNA Cancer Vaccine Market Size, Trends and Insights By Cancer Type (Melanoma, Lung Cancer (NSCLC), Prostate Cancer, Pancreatic Cancer, Colorectal Cancer), By Application/Use Case (Therapeutic Cancer Vaccines, Preventive/Prophylactic Cancer Vaccines), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Carriers, Electroporation), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Peptide Cancer Vaccine Market: Peptide Cancer Vaccine Market Size, Trends and Insights By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Burial Insurance Market: Burial Insurance Market Size, Trends and Insights By Coverage (Level Death Benefit, Guaranteed Acceptance, Modified or Graded Death Benefit), By End Use (Over 50, Over 60, Over 70, Over 80), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Organoids and Spheroids Market: Organoids and Spheroids Market Size, Trends and Insights By Organoids Type (Neural Organoids, Hepatic Organoids, Intestinal Organoids, Other Organoids), By Spheroids Type (Multicellular Tumor Spheroids (MCTS), Neurospheres, Mammospheres, Hepatospheres, Embryoid Bodies), By Organoids Source (Primary Tissues, Stem Cells), By Spheroids Source (Cell Line, Primary Cell, iPSCs Derived Cells), By End User (BioSource and Pharmaceutical Industries, Academic & Research Institutes, Hospitals and Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Medical Education Market: Medical Education Market Size, Trends and Insights By Delivery Mode (Classroom-based Training, E-learning Solutions, Online Learning, Simulation-based Learning, AR/VR-based Training, AI-powered Learning), By End User Type (Medical Schools and Universities, Hospitals and Healthcare Organizations, Independent Training Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Electrophysiology Devices Market: Electrophysiology Devices Market Size, Trends and Insights By Type (Ablation Catheters, Diagnostic Catheters, Mapping System, Accessories, Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, Others), By End User (Hospitals & ASCs, Specialty Clinics & Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Vitreous Tamponades Market: Vitreous Tamponades Market Size, Trends and Insights By Product Type (Gaseous Tamponades, Liquid Tamponades, Silicone Oil, Perchloroethane, Others), By Application (Retinal Detachment, Macular Hole, Endophthalmis, Intraocular Tumours, Vitreous Haemorrhage, Others), By End User (Hospitals, Ophthalmology Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 The Neoantigen Cancer Vaccine Market is segmented as follows: By Product Personalised neo-antigen vaccine Off-the-shelf neoantigen vaccine By Neoantigen Type Synthetic Long Peptide Nucleic acid Dendritic cell Tumour cell By Route of Administration Intravenous Intramuscular Transdermal Click Here to Get a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Neoantigen Cancer Vaccine Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Neoantigen Cancer Vaccine Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Neoantigen Cancer Vaccine Market? What Was the Capacity, Production Value, Cost and PROFIT of the Neoantigen Cancer Vaccine Market? What Is the Current Market Status of the Neoantigen Cancer Vaccine Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Neoantigen Cancer Vaccine Market by Considering Applications and Types? What Are Projections of the Global Neoantigen Cancer Vaccine Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Neoantigen Cancer Vaccine Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Neoantigen Cancer Vaccine Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Neoantigen Cancer Vaccine Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Neoantigen Cancer Vaccine Industry? Click Here to Access a Free Sample Report of the Global Neoantigen Cancer Vaccine Market @ Reasons to Purchase Neoantigen Cancer Vaccine Market Report Neoantigen Cancer Vaccine Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Neoantigen Cancer Vaccine Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Neoantigen Cancer Vaccine Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Neoantigen Cancer Vaccine Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Neoantigen Cancer Vaccine market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Neoantigen Cancer Vaccine market analysis. The competitive environment of current and potential participants in the Neoantigen Cancer Vaccine market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Neoantigen Cancer Vaccine market should find this report useful. The research will be useful to all market participants in the Neoantigen Cancer Vaccine industry. Managers in the Neoantigen Cancer Vaccine sector are interested in publishing up-to-date and projected data about the worldwide Neoantigen Cancer Vaccine market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Neoantigen Cancer Vaccine products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Neoantigen Cancer Vaccine Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Neoantigen Cancer Vaccine Research Report | Fast Delivery Available - [220+ Pages] @ in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
Immunotherapy Drugs (Monoclonal Antibodies, Immunomodulators, Vaccine) Market Size, Share & Trends Analysis and Growth Forecasts, 2025-2030
The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of 11.20%, driven by increased awareness of chronic diseases and supportive government policies. Rising adoption of targeted therapies, such as AstraZeneca's Enhertu for breast cancer, is key. Monoclonal antibodies and cancer treatments dominate the market, with North America leading due to high immunotherapy adoption and supportive policies. Immunotherapy Drugs Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030" has been added to offering. The Immunotherapy Drugs Market is poised for explosive growth, escalating from USD 257.60 Billion in 2024 to an anticipated USD 486.36 Billion by 2030, reflecting a robust CAGR of 11.20% This growth trajectory is underpinned by heightened awareness of chronic conditions such as cancer, autoimmune, inflammatory, and infectious diseases, coupled with favorable government policies facilitating drug approval pathways. The increasing adoption of targeted therapies for chronic disease management is further amplifying the market demand for immunotherapy drugs. Remarkable advancements in the sector include the U.S. approval of Enhertu (trastuzumab) for HER2-positive breast cancer by AstraZeneca and Daiichi Sankyo in May 2022, and the EU's endorsement of F. Hoffmann-La Roche Ltd.'s Tecentriq for NSCLC in June 2022. Simultaneously, expanded research and development, particularly in emerging markets, aligns with industry growth strategies. Novartis AG's collaboration with BeiGene, Ltd. for ociperlimab in December 2021 exemplifies such strategic R&D initiatives to broaden their immune-oncology pipeline. Boosting market impetus is Pfizer, Inc.'s positive phase 2b/3 trial outcomes for ritlecitinib, targeting alopecia areata, shared in August 2021. The global rise in cancer incidences further propels the demand for immunotherapy solutions. According to Globocan, 19.3 million new oncology cases were recorded in 2020, with projections indicating a 21% rise in European cancer incidences by 2040, as per the European Society of Medical Oncology, thus heightening the need for effective immunotherapy drugs. Immunotherapy Drugs Market Report Highlights The monoclonal antibodies segment dominated with a massive 76.2% market share in 2024, driven by extensive R&D and favorable government initiatives. Demand for biologics treatments for chronic diseases like cardiovascular, respiratory, and autoimmune disorders is a primary growth driver. The cancer segment commanded a 91.4% market revenue share in 2024, fueled by a surge in global cancer cases and better healthcare infrastructure in developing regions. North America led the global immunotherapy market, holding a 49.9% revenue share in 2024, attributed to high immunotherapy adoption, favorable reimbursement policies, and increased healthcare investment. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into key regional and segmental dynamics. Competitive Landscape: Understand the positioning of leading players in the market. Future Trends: Uncover trends and drivers influencing market direction. Actionable Recommendations: Leverage insights to identify new revenue opportunities and inform strategic directions. Key Attributes: Report Attribute Details No. of Pages 100 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $257.6 Billion Forecasted Market Value (USD) by 2030 $486.36 Billion Compound Annual Growth Rate 11.2% Regions Covered Global Companies Featured Amgen Inc. Novartis AG AbbVie Inc. Pfizer Inc. F. Hoffmann-La Roche Ltd Johnson & Johnson Services, Inc. AstraZeneca GSK plc. Sanofi Bayer AG For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Immunotherapy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Medscape
09-05-2025
- Health
- Medscape
Pembrolizumab for Advanced Melanoma: Is It Worth It?
In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential for side effects, which can be severe and occur in more than half of all patients. Oncologists need to weigh the risk of those side effects against the strong evidence supporting the effectiveness of pembrolizumab to improve survival. More often than not, those scales tip toward using the drug to treat advanced melanoma, experts say. Evidence has accumulated about which types of patients may be more susceptible to drug-related toxicities, how oncologists and other providers in the multidisciplinary team can manage those toxicities, and which treatment protocols may be most effective. Today, pembrolizumab is indicated for the treatment of about 20 types of cancer, but the first indication for which the US Food and Drug Administration (FDA) approved it was advanced or unresectable melanoma in people who had already tried ipilimumab and a BRAF inhibitor if their tumors had a BRAF mutation. It was the first immune checkpoint inhibitor (ICI) targeting programmed cell death 1 (PD-1) approved by the FDA. While it has been shown to extend life expectancy in melanoma and other types of cancers compared with ipilimumab, an anti–cytotoxic T lymphocyte antigen 4 (CTLA-4), and other older treatments, the side effects of pembrolizumab have been well-documented, particularly higher-grade toxicities (grades 3-5). Researchers who have studied the drug told Medscape Medical News that years of experience have demonstrated pembrolizumab is safe to use in just about any patient with advanced melanoma. The approval for pembrolizumab for advanced melanoma was based on the phase 3 KEYNOTE-006 trial, which found that the overall survival rate at 33 months was 50% vs 39% in patients on pembrolizumab vs ipilimumab. The rate of grade 3-5 adverse events (AEs) in the trial was 13%-16% for those on pembrolizumab and 20% for those on ipilimumab. A 10-year follow-up of the KEYNOTE-006 trial reported an overall survival rate of 34% for those on pembrolizumab and 23.6% for those on ipilimumab. Who Can Be on Pembrolizumab? 'I think you can consider trying it in any patient,' Omid Hamid, MD, chief of Research and IM/Oncology at Cedars-Sinai The Angeles Clinic and Research Institute, Los Angeles, and co-author of a safety evaluation published last year of almost 9000 patients in 31 clinical trials of pembrolizumab, said. Exceptions may be reinitiating pembrolizumab in a patient who had to halt treatment after a life-threatening AE or any patient with connective tissue disease or who has had a transplant, Hamid said. The 2024 safety evaluation included patients with advanced melanoma in the pivotal phase 3 KEYNOTE-006 trial. The study also identified other patient conditions that may give oncologists pause before using pembrolizumab: Anemia, pneumonia, hematologic malignancies, myocarditis, and gastric bleeding and myositis. 'The myocarditis, the myositis that comes with the myasthenia has a significant mortality associated with it, about 20%, so we need to understand that,' Hamid said. Sapna Patel, MD, a professor of oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado, led a phase 2 trial, known as SWOG S1801, that randomly assigned patients with surgically resectable stage IIIB-IVC melanoma to two pembrolizumab regimens: One with three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) and the second with surgery followed by 200 mg pembrolizumab every 3 weeks for 18 doses for about 1 year or until disease recurrence or unacceptable toxic events developed (adjuvant-only group). Event-free survival at 2 years was 72% in the former group vs 49% in the latter. Neoadjuvant-adjuvant pembrolizumab is indicated for patients with melanoma involving lymph nodes, particularly when the lymph nodes are readily measured on cross-sectional imaging or palpable on clinical exam, Patel said. 'We're currently investigating whether this can be expanded to other stages of melanoma,' she said. 'It is also approved to be given entirely postoperatively in the adjuvant setting, as well as for metastatic melanoma that has spread to distant parts of the body.' Patel called SWOG S1801 'a practice-changing trial' that showed that using the standard regimen of 18 doses of pembrolizumab before and after the surgery instead of giving all the doses after surgery can yield superior results, Patel told Medscape Medical News . Who May Not Be Good Candidates for Adjuvant Pembrolizumab? Patients with concurrent autoimmune conditions and those of advanced age who may not derive a long-term benefit in reducing recurrence risk may not be good candidates for adjuvant pembrolizumab, said Jason Luke, MD, director of the Immunotherapy and Drug Development Center at the University of Pittsburgh, Pittsburgh. Luke led the long-term follow-up of the pivotal KEYNOTE-716 trial of patients on adjuvant pembrolizumab with resected stage IIB/IIC melanoma, which found that recurrence-free survival at 48 months was 71.3% for pembrolizumab and 58.3% for placebo. The trial did not reveal any new safety signals. 'Patients with active autoimmune disease requiring treatment or organ transplant recipients may not be optimal candidates for this type of treatment,' Patel added. Similarly, she said, patients on chronic immune suppression would not likely benefit from treatment with an ICI. Even when side effects occur, oncologists should consider whether to discontinue pembrolizumab treatment carefully, Hamid said. 'There are times where you might think to discontinue it, but in scenarios where this is a life-threatening disease or you have other options that limit their lifespan and there may be an imminent cause of mortality, pembrolizumab would be indicated despite the potential side effects,' he said. Safety Profile The safety evaluation Hamid co-authored found that more than half of all patients had an any-cause grade 3-5 AE, and about 1 in 8 discontinued treatment. However, 6% of toxicities were immune-mediated, which he described as 'very low.' This year a real-world study from Northern Ireland found that even low-grade immune-related AE (irAE) toxicities in patients on adjuvant pembrolizumab for stage III melanoma could have a significant impact. Up to one third of them had to stop treatment. In this study, 70% of patients had a treatment-related toxicity, with 51% of all patients having a grade 1-2 toxicity. Among patients with only low-grade toxicity, 15% required hospitalized and 33% required immunosuppression with oral corticosteroids treatment. But steroid treatment comes with its own challenges, the study authors noted. 'Steroid tapering should be gradual as premature discontinuation may lead to relapse,' they wrote. However, long-term steroid use carries a risk for bone loss, particularly in patients aged 50 years or older. 'The risk of bone loss may be observed even at low doses and within the first month of treatment,' they wrote. Some patients may not respond to steroids for irAEs as shown in a different study, where 6.2% of patients with melanoma treated with checkpoint inhibitors did not respond to steroids. In patients with grade 2 toxicities who discontinue therapy, the Northern Ireland researchers wrote, 'these real-world data suggest that clinicians may be cautious' when resuming therapy. An analysis of the FDA AE database focused on cardiac AEs linked to pembrolizumab. The study looked at 6719 ICI-related cardiac AEs, more than one third (34.3%) of which were fatal. The analysis found that 17.3% of all pembrolizumab-associated AEs were cardiac in nature. Pembrolizumab was found to be more often reported with myocarditis, pericardial disease, heart failure, and atrial fibrillation than other drugs in the FDA database, with myocarditis being the most significant. However, the study did not specify cancer types or stages. In melanoma, the safety profile of pembrolizumab is comparable to that of other checkpoint inhibitors. The pivotal CheckMate 067 trial, which evaluated the combination of nivolumab, an anti–PD-1 agent like pembrolizumab, and ipilimumab against either drug alone in patients with melanoma, reported grade 3 or higher treatment-related AEs in approximately 59% of patients on combination therapy, with nearly 10% having to stop treatment. Survival Outcomes and AEs In the phase 2 SWOG S1801 trial, the incidence of AEs of grade 3 or higher was similar in both neoadjuvant-adjuvant and adjuvant-only treatment groups (12% and 14%, respectively), and significantly lower than other studies have found, study leader Patel said. The study did not specify irAEs. Hamid said that most pembrolizumab-related AEs 'are manageable and can get back to baseline.' Symptoms of irAEs can occur at 10 weeks into therapy or later, he said. Adrenal insufficiency, for example, occurred within about 6 months. The most commonly reported irAEs were hypothyroidism, pneumonitis, hyperthyroidism, colitis, and severe skin reactions, Hamid said. 'Any symptom needs to be looked at and considered in the setting of an immune-mediated toxicity,' Hamid said. Alternative to Pembrolizumab When pembrolizumab may not be optimal for treating melanoma, the use of first-line immunotherapy with alternative treatments and regimens might be. Hamid noted the phase 2 SECOMBIT trial showed that first-line immunotherapy followed by combination BRAF and MEK inhibition provided a survival benefit in patients with untreated BRAFV600 -metastatic melanoma. SECOMBIT included a treatment arm in which patients received 8 weeks of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib, followed by the combination of nivolumab with ipilimumab until PD — a regimen the study termed the 'sandwich' arm. That arm had a 4-year total progression survival rate of 54% vs 29% for the arm taking encorafenib plus binimetinib until PD followed by ipilimumab and nivolumab, and 55% for the arm that started with ipilimumab and nivolumab until PD then switched to encorafenib and binimetinib. 'It's the fact that immunotherapy takes time to work, so patients with aggressive high-tumor fraction growth may want to initially involve some form of priming dose,' Hamid said. 'For those who are BRAF -mutated, a lead-in with BRAF inhibition, with BRAF and MEK combination therapy as per the SECOMBIT trial, may be indicated.' Another option is what Patel called 'flipped dosing,' which involves nivolumab plus ipilimumab for two doses. Another alternative to pembrolizumab in advanced melanoma is nivolumab plus relatlimab, a checkpoint inhibitor that targets the lymphocyte-activation gene 3, Patel said. 'Treatment for melanoma has dramatically changed over the past 10-15 years, moving from a general lack of treatment options to now a plethora of options,' Luke said. He noted the multitude of options, besides the ICIs such as pembrolizumab and nivolumab, include combinations of anti–PD-1 with anti-CTLA4 and anti-LAG3 agents, BRAF and MEK inhibition as targeted therapy, adoptive cell transfer of tumor-infiltrating lymphocytes, oncolytic viruses, and CD3-bispecific therapies. The choices can be 'daunting' for patients, according to Luke. While there are several treatment options, overall, there is strong evidence supporting the life-extending effects of pembrolizumab despite the drug's potential side effects. Hamid disclosed having financial relationships with Alkermes, Amgen, Bactonix, BeiGene, BioAtla, Bristol Myers Squibb, Eisai Biotech, Roche/Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instil Bio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, NGM Bio, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, and Zelluna. Luke disclosed having financial relationships with AbbVie, Agenus, AstraZeneca, Bayer, Bristol Myers Squibb, Clasp, Curadev, Eisai, EMD Serono, Geneos, Gilead, HotSpot, Krystal, Janssen, Ikena, Immatics, Incyte, IO Biotech, iTeos, LegoChem, Lyvgen, Merck, Mersana, Novartis, Pfizer, Pioneering Medicines, Regeneron, Replimune, Storm, Sumitomo, Synlogic, and Teva. Patel disclosed having financial relationships with Bristol Myers Squibb, Cardinal Health, Ideaya, IO Biotech, Merck Sharpe and Dohme, Natera, Novartis, OncoSec, Pfizer, Replimune, Scancell, TriSalus, Veda Trials, Foghorn Therapeutics, InxMed, Lyvgen, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, and TriSalus Life Sciences. No funding details were reported by the authors of the Northern Island study. One author of that paper disclosed receiving honoraria from DePuy companies and having other ties with various organizations. Another author reported having a consulting or advisory role with Bristol Myers Squibb UK.
